PTGS2 and Stroke: Using phenotypic screening assays directed against some of the exacerbating mechanisms (mitochondrial dysfunction, oxidative stress glutamate toxicity) underlying deficits resulting from activation of the stroke cascade, CNB-001 has been shown to support cell survival [5], CNB-001 also a potent 5-lipoxygenase inhibitor (5-LOX) [4], anti-apoptotic and antioxidant [6], a negative regulator of inflammation [down-regulates, 5-LOX, cyclooxygenase-2 (COX-2), interleukin-6 (IL-6)] [3,7,8], and an activator of brain-derived neurotrophic factor (BDNF) and its signaling pathways [3].